Mylan CEO underestimated EpiPen profits by 60%

27 September 2016

When testifying before US Congress last week, the chief executive of Netherlands-incorporated drugmaker Mylan (Nasdaq: MYL) told members that her company’s profits from the EpiPen Auto-Injector (epinephrine injection, USP) were 60% lower than they actually were.

The company clarified figures given to the House last week by Heather Bresch, who said the Mylan made $100 for a two-pack of the injectors, which have a list price of $608.

Ms Bresch’s figure was reached by Mylan applying the statutory US corporate tax rate of 37.5%, which was in fact five times higher than the company’s overall tax rate last year, The Wall Street Journal has elicited.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK